Literature DB >> 33384321

Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics.

Andrew M Scott1, Lisa Bodei2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33384321      PMCID： PMC8882880          DOI： 10.2967/jnumed.120.254995

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  7 in total

Review 1.  Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy.

Authors:  Lisa Bodei; Heiko Schöder; Richard P Baum; Ken Herrmann; Jonathan Strosberg; Martyn Caplin; Kjell Öberg; Irvin M Modlin
Journal:  Lancet Oncol       Date:  2020-09       Impact factor: 41.316

2.  Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.

Authors:  Clemens Kratochwil; Frederik L Giesel; Claus-Peter Heussel; Daniel Kazdal; Volker Endris; Cathleen Nientiedt; Frank Bruchertseifer; Maximilian Kippenberger; Hendrik Rathke; Jonas Leichsenring; Markus Hohenfellner; Alfred Morgenstern; Uwe Haberkorn; Stefan Duensing; Albrecht Stenzinger
Journal:  J Nucl Med       Date:  2019-10-10       Impact factor: 10.057

3.  BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.

Authors:  Hojjat Ahmadzadehfar; Florian Gaertner; Philipp S Lossin; Bettina Schwarz; Markus Essler
Journal:  Clin Nucl Med       Date:  2018-08       Impact factor: 7.794

4.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Authors:  Alan L Ho; Ravinder K Grewal; Rebecca Leboeuf; Eric J Sherman; David G Pfister; Desiree Deandreis; Keith S Pentlow; Pat B Zanzonico; Sofia Haque; Somali Gavane; Ronald A Ghossein; Julio C Ricarte-Filho; José M Domínguez; Ronglai Shen; R Michael Tuttle; Steve M Larson; James A Fagin
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

5.  PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.

Authors:  Lisa Bodei; Mark S Kidd; Aviral Singh; Wouter A van der Zwan; Stefano Severi; Ignat A Drozdov; Jaroslaw Cwikla; Richard P Baum; Dik J Kwekkeboom; Giovanni Paganelli; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-26       Impact factor: 9.236

Review 6.  Cancer pharmacogenomics: strategies and challenges.

Authors:  Heather E Wheeler; Michael L Maitland; M Eileen Dolan; Nancy J Cox; Mark J Ratain
Journal:  Nat Rev Genet       Date:  2012-11-27       Impact factor: 53.242

7.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01
  7 in total
  2 in total

1.  The cultivation of supply side data science in medical imaging: an opportunity to define the future of global health.

Authors:  Adam Kesner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01       Impact factor: 9.236

2.  Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.

Authors:  Catherine Meyer; Vikas Prasad; Andreea Stuparu; Peter Kletting; Gerhard Glatting; Jonathan Miksch; Christoph Solbach; Katharina Lueckerath; Lea Nyiranshuti; Shaojun Zhu; Johannes Czernin; Ambros J Beer; Roger Slavik; Jeremie Calais; Magnus Dahlbom
Journal:  EJNMMI Res       Date:  2022-10-01       Impact factor: 3.434
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.